What is Co-Dx?
Co-Diagnostics, Inc., operating as Co-Dx, is a Salt Lake City-based entity specializing in the development, manufacturing, and sale of reagents for molecular diagnostic tests. The company's core offering includes the Co-Dx PCR platform, which enables polymerase chain reaction (PCR) testing in point-of-care and at-home settings. Co-Dx's diagnostic test portfolio spans a wide range of infectious diseases, including COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. Beyond human health, the company also develops molecular tools for agricultural applications, such as identifying genetic traits in plant and animal genomes, and for detecting diseases carried by mosquitos. Their innovative approach aims to democratize access to advanced diagnostic capabilities, bringing PCR technology closer to patients and various application sites.
How much funding has Co-Dx raised?
Co-Dx has raised a total of $13.1M across 4 funding rounds:
Debt
$750K
Stock Offering
$7.1M
Grant
$2.3M
Stock/Share Issuance
$3M
Debt (2016): $750K, investors not publicly disclosed
Stock Issuance/Offering (2017): $7.1M, investors not publicly disclosed
Grant (2023): $2.3M supported by Bill & Melinda Gates Foundation
Stock/Share Issuance (2026): $3M, investors not publicly disclosed
Key Investors in Co-Dx
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation is a prominent philanthropic organization dedicated to improving global health and reducing poverty. Their investment in Co-Dx likely reflects a shared commitment to advancing accessible diagnostic solutions for critical health challenges.
What's next for Co-Dx?
The recent major strategic investment and the context of enterprise-level funding suggest Co-Dx is poised for significant scaling and market expansion. This capital infusion is likely to accelerate the development of new diagnostic assays, enhance manufacturing capabilities, and broaden the company's global reach. The company's focus on point-of-care and at-home testing aligns with the growing demand for accessible and rapid diagnostic solutions, positioning Co-Dx for continued growth in the competitive health tech and biotech sectors. Future endeavors may include further diversification of their test offerings and strategic partnerships to penetrate new markets.
See full Co-Dx company page
